Colony stimulating factor-1 (CSF-1) recruits tumor-infiltrating myeloid cells (TIMs) that suppress tumor immunity, including M2 macrophages and myeloid derived suppressor cells (MDSC). The CSF-1 receptor (CSF-1R) is a tyrosine kinase that is targetable by small molecule inhibitors such as PLX3397. In this study, we used a syngeneic mouse model of BRAFV600E-driven melanoma to evaluate the ability of PLX3397 to improve the efficacy of adoptive T-cell therapy (ACT). In this model, we found that combined treatment produced superior anti-tumor responses compared with single treatments. In mice receiving the combined treatment, a dramatic reduction of TIMs and a skewing of 
Introduction
Established solid tumors consist of both transformed neoplastic cells and nontransformed host cells such as stromal cells, lymphocytes, dendritic cells, macrophages, and MDSC. In order to escape immune responses, tumor cells manipulate the surrounding tumor microenvironment by producing cytokines that suppress cytolytic Tcells and recruit immune suppressive cells (1) (2) (3) . CSF-1 is a cytokine frequently produced by several cancers, including melanoma (4, 5) . The secreted CSF-1 binds to the tyrosine kinase receptor CSF-1R on the myeloid cells, which results in increased proliferation and differentiation of myeloid cells into type M2 macrophages and MDSC, and their recruitment into tumors (6, 7) . The M2-polarized macrophages and MDSC use several mechanisms to induce an immune suppressive tumor environment, such as the release of arginase I or inducible nitric oxide synthase (iNOS), leading to T-cell inhibition (1) . Therefore, an immune suppressive tumor milieu mediated by CSF-1 may limit the anti-tumor activity of tumor immunotherapy and lead to low response rates (3) .
In prior studies, we have established a BRAF V600E mutant murine melanoma cell line, SM1, to provide a relevant model of melanoma in fully syngeneic immunocompetent mice (8) . BRAF V600E is the driver oncogene in approximately 50% of human melanomas (9) . Besides being driven by the BRAF V600E oncogene, SM1 has multiple genomic aberrations in a pattern similar to 108 human melanoma cell lines based on results of high-density single nucleotide polymorphism (SNP)/copy number alteration (CNA)
arrays. It includes amplification of oncogenic BRAF V600E and of the microphthalmiaassociated transcription factor (MITF), and a deletion of CDKN2A. In the SM1 model, adoptive cell transfer (ACT) of melanoma targeted T-cells induces anti-tumor responses that are enhanced by the addition of the BRAF inhibitor vemurafenib (8) . In addition, this same mouse model has been used to test the anti-tumor effects of several immune modulating antibodies, including anti-CTLA4, anti-PD-1, anti-Tim3 and agonistic anti-CD137 (41BB) (10) . Only anti-CD137 had significant anti-tumor activity alone or in combination with BRAF inhibitor therapy, suggesting that there may be factors in the tumor microenvironment that inhibit the effector arm of the immune system.
PLX3397 is a potent tyrosine kinase inhibitor (TKI) selected for its ability to inhibit CSF-1R. It is currently in clinical development as a single agent or in combination therapy for the treatment of patients with glioblastoma (GBM), breast cancer, and other cancers through its inhibition of the CSF-1R, and also acute myelogenous leukemia through its inhibition of FLT3-ITD. In preclinical models, CSF-1R inhibitors including PLX3397 have been reported to inhibit the immune suppressive tumor milieu and facilitate immune responses to cancer (11) (12) (13) (14) . We hypothesized that a combination of PLX3397 and ACT immunotherapy would improve the tumor microenvironment through the inhibition of immunosuppressive myeloid cells resulting in better T cell antitumor functions. Our results demonstrate significantly enhanced efficacy of the combined treatment, mediated by decreasing TIMs and increasing activated TILs compared with either of the single treatment groups. were conditioned for ACT with a lymphodepleting regimen of 500 cGy of total body irradiation (TBI). Then they received 2 x 10 5 or 1 x 10 6 OVA 257-264 peptide-activated OT-1 splenocytes or gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide-activated pmel-1 splenocytes intravenously (i.v.) as previously described (15) . In both cases, the ACT was followed by three days of daily i.p. Biosciences), followed by Flow-Jo software (Tree-Star, Ashland, OR) analysis as previously described (16) . Intracellular interferon gamma (IFN-γ) staining was done as previously described (16) .
Materials and Methods

Mice
Immunofluorescence Imaging. Staining was performed as previously described (15) .
Briefly, sections of OCT (Sakura Finetek, Torrance, CA) cryopreserved tissues were blocked in donkey serum/ PBS and incubated with primary antibodies to Gr-1 (BD Biosciences) or F4/80 (Abcam), followed by secondary donkey anti-rat antibodies conjugated to DyLight488 (Jackson Immunoresearch Laboratories, West Grove, PA).
Negative controls consisted of isotype matched rabbit or rat IgG in lieu of the primary antibodies listed above. DAPI (4,6-diamidino-2-phenylindole) was used for the visualization of nuclei. Immunofluorescence images were taken in a fluorescence microscope (Axioplan-2; Carl Zeiss Microimaging, Thornwood, NY).
Bioluminescence imaging (BLI).
OT-1 or pmel-1 splenocytes were retrovirallytransduced to express firefly luciferase as previously described (15) , and used for ACT.
BLI was performed with a Xenogen IVIS 200 Imaging System (Xenogen/Caliper Life Sciences, Hopkinton, MA) as previously described (15) . 
Results
PLX3397
does not have direct cytotoxic effects against SM1 and preserves splenocytes. We tested the effects of single agent PLX3397 against SM1 using an in vitro MTS cell proliferation assay after 72 hours of exposure to rule out a potential direct anti-tumor effect of this CSF-1R inhibitor in the SM1 murine melanoma cell line. An IC 50 was not reached even at 1 μM (Fig. 1a) . In addition to its resistance in MTS assays, exposure of SM1 to PLX3397 at the range of concentrations between 10 nM and 1 µM showed no inhibition of the downstream MAPK signaling pathway (Fig. 1b) . SM1 does not express either CSF-1R or c-kit by FACS analysis and gene expression profiling (data not shown); these are the two main targets of PLX3397. SM1 also produces high levels of CSF-1 protein and its level is not affected by PLX3397 at 1 µM (Supplemental Fig. 1 ).
We then ruled out that PLX3397 had a potential detrimental effect against T-cells.
Increasing concentrations of PLX3397 did not negatively alter the viability of murine splenocytes after 72 hours of treatment (Fig. 1c) . In contrast, 1 µM of PLX3397 was enough to down-regulate pErk level and to kill cells that were dependent on CSF-1/CSF-1R for growth such as myeloid cells and microglia cells (12, 17) . Therefore, since single agent PLX3397 did not affect the viability of either SM1 cells or murine splenocytes, this supports SM1 as a permissive model for testing the effects of PLX3397 to improve the anti-tumor activity of ACT immunotherapy. (8) (Fig. 2c) . In replicate studies, the combined therapy with pmel-1 ACT and PLX3397 also had superior anti-tumor response compared with either single agent therapy alone and improved survival ( 
Decrease in tumor infiltrating macrophages by inhibition of CSF-1R by PLX3397.
To analyze whether PLX3397 changed the magnitude of TIMs, including macrophages and MDSC, we analyzed their presence in tumors by immunofluorescence. There was a decrease in the quantity of F4/80(+) macrophages in both the PLX3397 single agent group and the combined group compared to vehicle or ACT single treatment groups (Fig. 3a) . Analysis of tumors, spleens, lungs, blood, and bone marrow from mice treated with PLX3397 demonstrated that the effects of PLX3397 were specific for intratumoral macrophages as opposed to a systemic depletion of macrophages. There was a local (tumor) decrease in quantity of F4/80(+) CD11b(+) macrophages but no significant decrease systemically ( Fig. 3b and 3d; Supplemental Fig. 3 ). To further characterize the phenotype of the remaining macrophages, MHCII expression was analyzed by FACS. There was a shift in macrophage phenotype from MHCII low to MHCII hi upon treatment with PLX3397 ( Fig. 3c and 3d 
Effect of CSF-1 or macrophage depletion overlapped with the effects of PLX3397.
In order to confirm the role of CSF-1 in the activity of PLX3397, PLX3397 treatment was combined with anti-CSF-1 antibody in mice that received ACT with pmel-1 splenocytes.
There was no improvement in anti-tumor activity in the PLX3397, pmel-1 ACT and anti-CSF-1 antibody treatment groups, compared to mice receiving PLX3397 and pmel-1
ACT therapy with an isotype control antibody (Fig. 5a ), suggesting that the effects of PLX3397 and anti-CSF-1 antibody-mediated depletion might be overlapping. To determine if the target of PLX3397 was macrophages, mice with established SM1 
tumors were treated with PLX3397 in combination with clodronate, an agent that depletes macrophages. There was no enhanced anti-tumor response in the combined treatment group of PLX3397 and clodronate compared with either single treatment group (Fig. 5b) . These studies suggest that PLX3397 mediated its effects through inhibition of immune suppressive CSF-1-responding intratumoral macrophages. (Fig. 6a) . The quantitative analysis of T-cell-associated luciferase activity in mice treated with OT-1 ACT combined with PLX3397 showed increased accumulation within OVA antigenmatched tumors over time ( Fig. 6b; Supplemental Fig. 4a ). Further, we repeated the bioluminescence imaging using pmel-1 T-cells also labeled with the firefly luciferase transgene and used for ACT. Again, PLX3397 increased the expansion of pmel-1 T-cells distributed to gp100 positive antigen-matched SM1 tumors (Fig. 6c) . Mice that received pmel-1 ACT combined with PLX3397 also demonstrated an increased intratumoral accumulation of luciferase activity to tumors over time ( Fig. 6d; Supplemental Fig. 4b ).
PLX3397 increases
We then analyzed the activation state of TILs by detecting cytokine production. In two replicate experiments, TILs collected from mice treated with the combination of pmel-1 ACT and PLX3397 showed a higher ability to secrete IFN-γ and to respond to short term ex vivo restimulation with the gp100 antigen (Fig. 6e) . Therefore, treatment with PLX3397 increased both the number and functionality of adoptively transferred antitumor antigen-specific T-cells. 
The anti-tumor activity of PLX3397 is T-cell-dependent. Single agent PLX3397 treatment demonstrated a weak but reproducible anti-tumor response compared with vehicle control (Fig. 2b, 2c, and 5b) . We tested if this antitumor activity was mediated by endogenous cytotoxic CD8 T-cells. SM1 tumors were implanted in C57BL/6 mice without irradiation and received PLX3397 in combination with anti-CD8 antibody. The depletion of CD8+ cells abrogated the antitumor activity of single agent PLX3397 (Fig. 7a) . To further test the role of immune cells in the antitumor activity of PLX3397, immunodeficient NSG mice were implanted with SM1 tumors and dosed with PLX3397.
In these immunodeficient mice there was no anti-tumor activity of PLX3397 compared to mice receiving vehicle control (Fig. 7b ). Finally, we tested whether the anti-tumor effects of PLX3397 was also dependent on cytotoxic CD8 T-cells in the pmel-1 ACT model. C57BL/6 mice with established SM1 tumors were treated with a combination of PLX3397, anti-CD8 antibody, and pmel-1 ACT. There was no anti-tumor activity of pmel-1 ACT combined with PLX3397 in mice that received CD8 depleting antibody (Fig. 7c) .
Collectively, these studies highlight the role of CD8+ T-cells as effectors of the antitumor activity of PLX3397 in the SM1 murine melanoma model. We explored the potential mechanisms by which PLX3397 improves the anti-tumor effect of ACT. The myeloid cells infiltrating SM1 tumors are mainly macrophages. Our data demonstrate that PLX3397 decreases the quantity of macrophages locally in tumor.
Although the classification between M1 and M2 polarized macrophages is still controversial, MHCII is used as a marker to distinguish them (19) . With PLX3397 there is a skewing of the population of MHCII low to MHCII hi macrophages, consistent with a previous report (13) . By decreasing the presence of immune suppressive MHCII 
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